Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:aristolochic acid
go back to main search page
Accession:CHEBI:2825 term browser browse the term
Definition:A monocarboxylic acid that is phenanthrene-1-carboxylic acid that is substituted by a methylenedioxy group at the 3,4 positions, by a methoxy group at position 8, and by a nitro group at position 10. It is the most abundant of the aristolochic acids and is found in almost all Aristolochia (birthworts or pipevines) species. It has been tried in a number of treatments for inflammatory disorders, mainly in Chinese and folk medicine. However, there is concern over their use as aristolochic acid is both carcinogenic and nephrotoxic.
Synonyms:exact_synonym: 8-methoxy-6-nitrophenanthro[3,4-d][1,3]dioxole-5-carboxylic acid
 related_synonym: 3,4-methylenedioxy-8-methoxy-10-nitro-1-phenanthrenecarboxylic acid;   8-methoxy-6-nitrophenanthol (3,4-d) 1,3-dioxole-5-carboxylic acid;   Aristolochic acid I;   Formula=C17H11NO7;   InChI=1S/C17H11NO7/c1-23-12-4-2-3-8-9(12)5-11(18(21)22)14-10(17(19)20)6-13-16(15(8)14)25-7-24-13/h2-6H,7H2,1H3,(H,19,20);   InChIKey=BBFQZRXNYIEMAW-UHFFFAOYSA-N;   SMILES=COc1cccc2c1cc([N+]([O-])=O)c1c(cc3OCOc3c21)C(O)=O;   aristolochic acid A;   aristolochin
 xref: CAS:313-67-7;   KEGG:C08469;   KNApSAcK:C00001526;   KNApSAcK:C00027516;   LINCS:LSM-2373
 xref_mesh: MESH:C000228
 xref: PMID:21558304;   PMID:21719716;   PMID:22071594;   PMID:22118289;   PMID:22126455;   PMID:22245565;   PMID:22373701;   Reaxys:345159;   Wikipedia:Aristolochic_acid


show annotations for term's descendants           Sort by:
 
aristolochic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb1b ATP-binding cassette, subfamily B (MDR/TAP), member 1B multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of ABCB1B mRNA CTD PMID:23912714 NCBI chr 4:22,225,123...22,307,577
Ensembl chr 4:22,133,521...22,425,515
JBrowse link
G Abcc3 ATP binding cassette subfamily C member 3 increases expression
multiple interactions
EXP aristolochic acid I results in increased expression of ABCC3 mRNA
[aristolochic acid I co-treated with aristolochic acid II] results in increased expression of ABCC3 mRNA
CTD PMID:17483316, PMID:23912714 NCBI chr10:82,047,308...82,116,928
Ensembl chr10:82,047,863...82,117,109
JBrowse link
G Acot9 acyl-CoA thioesterase 9 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of ACOT9 mRNA CTD PMID:23912714 NCBI chr  X:43,543,069...43,592,200
Ensembl chr  X:43,543,070...43,592,200
JBrowse link
G Acsl1 acyl-CoA synthetase long-chain family member 1 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of ACSL1 mRNA CTD PMID:23912714 NCBI chr16:48,937,456...49,003,898
Ensembl chr16:48,937,456...49,003,246
JBrowse link
G Acsm2 acyl-CoA synthetase medium-chain family member 2 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of ACSM2A mRNA CTD PMID:23912714 NCBI chr 1:189,289,957...189,329,007
Ensembl chr 1:189,289,957...189,395,276
JBrowse link
G Acta2 actin alpha 2, smooth muscle multiple interactions
increases expression
ISO [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of ACTA2 mRNA; GREM1 mutant form inhibits the reaction [aristolochic acid I results in increased expression of ACTA2 protein]
aristolochic acid I results in increased expression of ACTA2 mRNA; aristolochic acid I results in increased expression of ACTA2 protein
CTD PMID:22525892, PMID:25663515, PMID:31048001 NCBI chr 1:252,537,614...252,550,394
Ensembl chr 1:252,537,615...252,550,394
JBrowse link
G Adap2 ArfGAP with dual PH domains 2 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of ADAP2 mRNA CTD PMID:23912714 NCBI chr10:67,494,851...67,527,582
Ensembl chr10:67,494,984...67,526,426
JBrowse link
G Akr1b8 aldo-keto reductase family 1, member B8 increases expression
multiple interactions
EXP aristolochic acid I results in increased expression of AKR1B8 mRNA
[aristolochic acid I co-treated with aristolochic acid II] results in increased expression of AKR1B8 mRNA
CTD PMID:17483316, PMID:23912714 NCBI chr 4:61,772,064...61,784,637
Ensembl chr 4:61,771,970...61,828,657
JBrowse link
G Akr7a3 aldo-keto reductase family 7 member A3 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of AKR7A3 mRNA CTD PMID:23912714 NCBI chr 5:157,801,120...157,813,756
Ensembl chr 5:157,801,163...157,813,756
JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO aristolochic acid I inhibits the reaction [Arachidonic Acid results in increased phosphorylation of AKT1 protein] CTD PMID:19344371 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Anxa13 annexin A13 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of ANXA13 mRNA CTD PMID:23912714 NCBI chr 7:98,217,642...98,270,442
Ensembl chr 7:98,217,642...98,270,110
JBrowse link
G Apoh apolipoprotein H multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of APOH mRNA CTD PMID:23912714 NCBI chr10:96,640,013...96,653,939
Ensembl chr10:96,639,924...96,653,938
JBrowse link
G Atg5 autophagy related 5 multiple interactions
increases response to substance
increases expression
EXP 3-methyladenine inhibits the reaction [aristolochic acid I results in increased expression of ATG5 protein]; ATG5 affects the reaction [aristolochic acid I results in increased cleavage of PARP1 protein]
ATG5 results in increased susceptibility to aristolochic acid I
CTD PMID:23939141 NCBI chr20:49,301,783...49,393,147
Ensembl chr20:49,318,308...49,393,140
JBrowse link
G Azgp1 alpha-2-glycoprotein 1, zinc-binding multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of AZGP1 mRNA CTD PMID:23912714 NCBI chr12:19,196,565...19,203,094
Ensembl chr12:19,196,611...19,202,647
JBrowse link
G B2m beta-2 microglobulin multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of B2M protein CTD PMID:23912714 NCBI chr 3:114,087,287...114,093,311
Ensembl chr 3:114,087,287...114,093,309
JBrowse link
G Bax BCL2 associated X, apoptosis regulator increases expression ISO aristolochic acid I results in increased expression of BAX protein CTD PMID:26656393, PMID:31048001 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Bcl2 BCL2, apoptosis regulator decreases expression ISO aristolochic acid I results in decreased expression of BCL2 protein CTD PMID:26656393, PMID:31048001 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Bcl6 BCL6, transcription repressor multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of BCL6 mRNA CTD PMID:23912714 NCBI chr11:80,255,790...80,279,075
Ensembl chr11:80,255,790...80,279,075
JBrowse link
G Becn1 beclin 1 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of BECN1 mRNA CTD PMID:23912714 NCBI chr10:89,209,944...89,225,297
Ensembl chr10:89,209,940...89,225,297
JBrowse link
G Blcap BLCAP, apoptosis inducing factor multiple interactions
decreases expression
ISO decitabine inhibits the reaction [aristolochic acid I results in decreased expression of BLCAP mRNA]; decitabine inhibits the reaction [aristolochic acid I results in decreased expression of BLCAP protein]
aristolochic acid I results in decreased expression of BLCAP mRNA; aristolochic acid I results in decreased expression of BLCAP protein
CTD PMID:29655784 NCBI chr 3:154,040,165...154,042,096
Ensembl chr 3:154,040,166...154,042,099
JBrowse link
G Bmp7 bone morphogenetic protein 7 multiple interactions
decreases expression
decreases response to substance
ISO aristolochic acid I results in decreased expression of and results in decreased activity of BMP7 protein; BMP7 protein inhibits the reaction [[aristolochic acid I co-treated with aristolochic acid II] results in increased expression of CTNNB1 protein]; BMP7 protein inhibits the reaction [[aristolochic acid I co-treated with aristolochic acid II] results in increased expression of VIM protein]; BMP7 protein promotes the reaction [[aristolochic acid I co-treated with aristolochic acid II] results in increased expression of VIM protein]; GREM1 mutant form inhibits the reaction [aristolochic acid I results in decreased activity of BMP7 protein]; GREM1 protein inhibits the reaction [BMP7 protein results in decreased susceptibility to aristolochic acid I]
aristolochic acid I results in decreased expression of BMP7 mRNA
CTD PMID:22525892, PMID:25663515 NCBI chr 3:170,879,972...170,955,820
Ensembl chr 3:170,879,973...170,955,399
JBrowse link
G C1qa complement C1q A chain multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of C1QA mRNA CTD PMID:23912714 NCBI chr 5:155,261,254...155,264,101
Ensembl chr 5:155,261,250...155,264,143
JBrowse link
G C1qc complement C1q C chain multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of C1QC mRNA CTD PMID:23912714 NCBI chr 5:155,255,013...155,258,631
Ensembl chr 5:155,255,005...155,258,392
JBrowse link
G C1s complement C1s multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of C1S mRNA CTD PMID:23912714 NCBI chr 4:157,143,592...157,155,592
Ensembl chr 4:157,143,592...157,155,609
JBrowse link
G C3 complement C3 increases secretion
increases expression
ISO aristolochic acid I results in increased secretion of C3 protein
aristolochic acid I results in increased expression of C3 mRNA
CTD PMID:31048001 NCBI chr 9:9,721,137...9,747,084
Ensembl chr 9:9,721,105...9,747,167
JBrowse link
G C3ar1 complement C3a receptor 1 increases expression
multiple interactions
ISO aristolochic acid I results in increased expression of C3AR1 mRNA; aristolochic acid I results in increased expression of C3AR1 protein
aristolochic acid I results in increased expression of and affects the secretion of C3AR1 protein
CTD PMID:31048001 NCBI chr 4:155,681,767...155,691,240
Ensembl chr 4:155,684,029...155,690,869
JBrowse link
G Ca8 carbonic anhydrase 8 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of CAR8 mRNA CTD PMID:23912714 NCBI chr 5:21,249,018...21,345,810
Ensembl chr 5:21,249,020...21,345,810
JBrowse link
G Cadps2 calcium dependent secretion activator 2 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of CADPS2 mRNA CTD PMID:23912714 NCBI chr 4:50,326,447...50,861,161
Ensembl chr 4:50,326,442...50,860,756
JBrowse link
G Calb1 calbindin 1 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of CALB1 protein CTD PMID:23912714 NCBI chr 5:29,538,380...29,562,774
Ensembl chr 5:29,538,380...29,562,773
JBrowse link
G Casp3 caspase 3 multiple interactions
increases expression
increases activity
ISO Acetylcysteine inhibits the reaction [aristolochic acid I results in increased activity of CASP3 protein]; Glutathione inhibits the reaction [aristolochic acid I results in increased activity of CASP3 protein]
aristolochic acid I results in increased expression of CASP3 protein
aristolochic acid I results in increased expression of CASP3 protein; aristolochic acid I results in increased expression of CASP3 protein modified form
CTD PMID:21300145, PMID:26656393, PMID:31048001 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Casp9 caspase 9 increases expression ISO aristolochic acid I results in increased expression of CASP9 protein modified form CTD PMID:26656393 NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
JBrowse link
G Ccdc80 coiled-coil domain containing 80 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of CCDC80 mRNA CTD PMID:23912714 NCBI chr11:60,645,660...60,679,249
Ensembl chr11:60,645,086...60,679,555
JBrowse link
G Ccl5 C-C motif chemokine ligand 5 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of CCL5 mRNA CTD PMID:23912714 NCBI chr10:70,739,764...70,744,303
Ensembl chr10:70,739,800...70,744,315
JBrowse link
G Ccn2 cellular communication network factor 2 multiple interactions ISO aristolochic acid I inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in decreased expression of CCN2 protein] CTD PMID:24412304 NCBI chr 1:21,851,657...21,854,773
Ensembl chr 1:21,851,660...21,854,773
JBrowse link
G Ccnb1 cyclin B1 decreases expression EXP aristolochic acid I results in decreased expression of CCNB1 mRNA CTD PMID:17483316 NCBI chr 2:30,782,133...30,791,106
Ensembl chr 2:30,783,915...30,791,221
JBrowse link
G Ccng1 cyclin G1 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of CCNG1 mRNA CTD PMID:23912714 NCBI chr10:25,903,925...25,910,298
Ensembl chr10:25,903,911...25,910,325
JBrowse link
G Cd36 CD36 molecule decreases expression ISO aristolochic acid I results in decreased expression of CD36 mRNA CTD PMID:31009690 NCBI chr 4:14,150,309...14,191,498
Ensembl chr 4:14,001,761...14,249,749
JBrowse link
G Cd3d CD3d molecule multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of CD3D mRNA CTD PMID:23912714 NCBI chr 8:49,282,502...49,287,095
Ensembl chr 8:49,282,460...49,287,110
JBrowse link
G Cd3g CD3g molecule multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of CD3G mRNA CTD PMID:23912714 NCBI chr 8:49,274,553...49,280,943
Ensembl chr 8:49,274,960...49,280,901
JBrowse link
G Cd68 Cd68 molecule multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of CD68 mRNA CTD PMID:23912714 NCBI chr10:56,268,726...56,270,605
Ensembl chr10:56,268,720...56,270,640
JBrowse link
G Cdh1 cadherin 1 multiple interactions
decreases expression
ISO [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of CDH1 mRNA; GREM1 mutant form inhibits the reaction [aristolochic acid I results in decreased expression of CDH1 protein]
aristolochic acid I results in decreased expression of CDH1 mRNA; aristolochic acid I results in decreased expression of CDH1 protein
CTD PMID:22525892, PMID:25663515, PMID:31048001 NCBI chr19:38,768,467...38,838,395
Ensembl chr19:38,768,467...38,838,395
JBrowse link
G Cdk1 cyclin-dependent kinase 1 decreases expression EXP aristolochic acid I results in decreased expression of CDK1 mRNA CTD PMID:17483316 NCBI chr20:20,576,341...20,591,510
Ensembl chr20:20,576,377...20,591,549
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A increases expression ISO aristolochic acid I results in increased expression of CDKN1A protein CTD PMID:31602497 NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
JBrowse link
G Ces3a carboxylesterase 3a increases expression EXP aristolochic acid I results in increased expression of CES3 mRNA CTD PMID:17483316 NCBI chr19:37,070,705...37,079,411 JBrowse link
G Cflar CASP8 and FADD-like apoptosis regulator multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of CFLAR mRNA CTD PMID:23912714 NCBI chr 9:65,534,608...65,586,395
Ensembl chr 9:65,534,704...65,587,251
JBrowse link
G Cks2 CDC28 protein kinase regulatory subunit 2 decreases expression EXP aristolochic acid I results in decreased expression of CKS2 mRNA CTD PMID:17483316 NCBI chr17:13,587,664...13,593,423
Ensembl chr17:13,587,665...13,593,423
JBrowse link
G Clec10a C-type lectin domain containing 10A multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of CLEC10A mRNA CTD PMID:23912714 NCBI chr10:56,764,927...56,769,447
Ensembl chr10:56,764,927...56,769,457
JBrowse link
G Cpt2 carnitine palmitoyltransferase 2 decreases expression ISO aristolochic acid I results in decreased expression of CPT2 mRNA CTD PMID:31009690 NCBI chr 5:127,505,646...127,523,016
Ensembl chr 5:127,505,614...127,523,089
JBrowse link
G Cry1 cryptochrome circadian regulator 1 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of CRY1 mRNA CTD PMID:23912714 NCBI chr 7:24,534,593...24,634,098
Ensembl chr 7:24,534,615...24,634,097
JBrowse link
G Cryab crystallin, alpha B multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of CRYAB mRNA CTD PMID:23912714 NCBI chr 8:55,178,543...55,182,546
Ensembl chr 8:55,178,289...55,182,545
JBrowse link
G Cs citrate synthase decreases expression ISO aristolochic acid I results in decreased expression of CS mRNA; aristolochic acid I results in decreased expression of CS protein CTD PMID:31009690 NCBI chr 7:2,752,680...2,778,963
Ensembl chr 7:2,752,680...2,778,963
JBrowse link
G Csad cysteine sulfinic acid decarboxylase increases expression ISO aristolochic acid I results in increased expression of CSAD mRNA CTD PMID:31009690 NCBI chr 7:143,781,520...143,810,880
Ensembl chr 7:143,781,702...143,793,970
JBrowse link
G Ctnnb1 catenin beta 1 multiple interactions ISO [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of CTNNB1 protein; BMP7 protein inhibits the reaction [[aristolochic acid I co-treated with aristolochic acid II] results in increased expression of CTNNB1 protein] CTD PMID:25663515 NCBI chr 8:129,601,511...129,628,378
Ensembl chr 8:129,617,812...129,627,372
JBrowse link
G Ctsd cathepsin D multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of CTSD mRNA CTD PMID:23912714 NCBI chr 1:215,541,570...215,553,446
Ensembl chr 1:215,541,542...215,553,451
JBrowse link
G Ctss cathepsin S multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of CTSS mRNA CTD PMID:23912714 NCBI chr 2:197,655,780...197,679,768
Ensembl chr 2:197,655,786...197,679,458
JBrowse link
G Ctsw cathepsin W multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of CTSW mRNA CTD PMID:23912714 NCBI chr 1:220,844,579...220,847,967
Ensembl chr 1:220,844,558...220,848,153
JBrowse link
G Cxcl9 C-X-C motif chemokine ligand 9 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of CXCL9 mRNA CTD PMID:23912714 NCBI chr14:17,228,832...17,233,743
Ensembl chr14:17,228,856...17,234,712
JBrowse link
G Cyb5a cytochrome b5 type A multiple interactions EXP [CYP2C11 protein co-treated with CYB5A protein] results in increased abundance of aristolochic acid I metabolite; [CYP2C11 protein co-treated with CYB5A protein] results in increased metabolism of aristolochic acid I; [CYP2C12 protein co-treated with CYB5A protein] results in increased abundance of aristolochic acid I metabolite; [CYP2C12 protein co-treated with CYB5A protein] results in increased metabolism of aristolochic acid I; [CYP2C13 protein co-treated with CYB5A protein] results in increased abundance of aristolochic acid I metabolite; [CYP2C13 protein co-treated with CYB5A protein] results in increased metabolism of aristolochic acid I; [CYP2C6V1 protein co-treated with CYB5A protein] results in increased abundance of aristolochic acid I metabolite; [CYP2C6V1 protein co-treated with CYB5A protein] results in increased metabolism of aristolochic acid I CTD PMID:21362632 NCBI chr18:81,694,818...81,726,821
Ensembl chr18:81,694,808...81,726,821
JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 increases abundance
increases metabolic processing
increases expression
multiple interactions
increases oxidation
EXP
ISO
CYP1A1 protein results in increased abundance of aristolochic acid I metabolite
CYP1A1 protein results in increased metabolism of aristolochic acid I
aristolochic acid I results in increased expression of CYP1A1 mRNA
1-phenylazo-2-naphthol promotes the reaction [aristolochic acid I results in increased expression of and results in increased activity of CYP1A1 protein]; [1-phenylazo-2-naphthol co-treated with aristolochic acid I] results in increased expression of CYP1A1 mRNA; aristolochic acid I results in increased expression of and results in increased activity of CYP1A1 protein; Oxygen deficiency affects the reaction [CYP1A1 protein results in increased metabolism of aristolochic acid I]
[CYP1A1 protein results in increased oxidation of aristolochic acid I] which results in increased chemical synthesis of aristolochic acid I metabolite; CYP1A1 protein results in increased reduction of and results in increased activity of aristolochic acid I; Oxygen deficiency affects the reaction [CYP1A1 protein results in increased metabolism of aristolochic acid I]
[[alpha-naphthoflavone results in decreased activity of CYP1A2 protein] co-treated with [alpha-naphthoflavone results in decreased activity of CYP1A1 protein]] inhibits the reaction [aristolochic acid I results in increased abundance of [7-(deoxyadenosin-N(6)-yl)aristolactam I co-treated with 7-(deoxyguanosin-N(2)-yl)aristolactam I co-treated with 7-(deoxyadenosin-N(6)--yl)aristolactam II]]; [CYP1A1 protein co-treated with CYP1A2 protein] affects the reaction [[Thioctic Acid results in decreased activity of POR protein] inhibits the reaction [aristolochic acid I results in increased abundance of [7-(deoxyadenosin-N(6)-yl)aristolactam I co-treated with 7-(deoxyguanosin-N(2)-yl)aristolactam I co-treated with 7-(deoxyadenosin-N(6)--yl)aristolactam II]]]; [CYP1A1 protein results in increased oxidation of aristolochic acid I] which results in increased abundance of aristolochic acid I metabolite; [ellipticine results in decreased activity of CYP1A1 protein] inhibits the reaction [aristolochic acid I results in increased abundance of [7-(deoxyadenosin-N(6)-yl)aristolactam I co-treated with 7-(deoxyguanosin-N(2)-yl)aristolactam I co-treated with 7-(deoxyadenosin-N(6)--yl)aristolactam II]]; CYP1A1 protein affects the reaction [[Thioctic Acid results in decreased activity of POR protein] inhibits the reaction [aristolochic acid I results in increased abundance of [7-(deoxyadenosin-N(6)-yl)aristolactam I co-treated with 7-(deoxyguanosin-N(2)-yl)aristolactam I co-treated with 7-(deoxyadenosin-N(6)--yl)aristolactam II]]]; CYP1A1 protein promotes the reaction [aristolochic acid I results in increased abundance of [7-(deoxyadenosin-N(6)-yl)aristolactam I co-treated with 7-(deoxyguanosin-N(2)-yl)aristolactam I co-treated with 7-(deoxyadenosin-N(6)--yl)aristolactam II]]; CYP1A1 protein results in increased reduction of and results in increased oxidation of and affects the activity of aristolochic acid I
CTD PMID:21362632, PMID:21932800, PMID:22086975, PMID:25230394, PMID:26845733 NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 increases abundance
increases metabolic processing
increases expression
multiple interactions
increases chemical synthesis
increases oxidation
EXP
ISO
CYP1A2 protein results in increased abundance of aristolochic acid I metabolite
CYP1A2 protein results in increased metabolism of aristolochic acid I
aristolochic acid I results in increased expression of CYP1A2 mRNA
[1-phenylazo-2-naphthol co-treated with aristolochic acid I] results in increased expression of CYP1A2 mRNA; [aristolochic acid I co-treated with 1-phenylazo-2-naphthol] results in increased expression of and results in increased activity of CYP1A2 protein; Oxygen deficiency affects the reaction [CYP1A2 protein results in increased metabolism of aristolochic acid I]
[CYP1A2 protein results in increased oxidation of aristolochic acid I] which results in increased chemical synthesis of aristolochic acid I metabolite; CYP1A2 protein results in increased reduction of and results in increased activity of aristolochic acid I; Oxygen deficiency affects the reaction [CYP1A2 protein results in increased metabolism of aristolochic acid I]
CYP1A2 protein results in increased chemical synthesis of aristolochic acid I metabolite
[[alpha-naphthoflavone results in decreased activity of CYP1A2 protein] co-treated with [alpha-naphthoflavone results in decreased activity of CYP1A1 protein]] inhibits the reaction [aristolochic acid I results in increased abundance of [7-(deoxyadenosin-N(6)-yl)aristolactam I co-treated with 7-(deoxyguanosin-N(2)-yl)aristolactam I co-treated with 7-(deoxyadenosin-N(6)--yl)aristolactam II]]; [CYP1A1 protein co-treated with CYP1A2 protein] affects the reaction [[Thioctic Acid results in decreased activity of POR protein] inhibits the reaction [aristolochic acid I results in increased abundance of [7-(deoxyadenosin-N(6)-yl)aristolactam I co-treated with 7-(deoxyguanosin-N(2)-yl)aristolactam I co-treated with 7-(deoxyadenosin-N(6)--yl)aristolactam II]]]; [CYP1A2 protein results in increased oxidation of aristolochic acid I] which results in increased abundance of aristolochic acid I metabolite; [furafylline results in decreased activity of CYP1A2 protein] inhibits the reaction [aristolochic acid I results in increased abundance of [7-(deoxyadenosin-N(6)-yl)aristolactam I co-treated with 7-(deoxyguanosin-N(2)-yl)aristolactam I co-treated with 7-(deoxyadenosin-N(6)--yl)aristolactam II]]; CYP1A2 protein promotes the reaction [aristolochic acid I results in increased abundance of [7-(deoxyadenosin-N(6)-yl)aristolactam I co-treated with 7-(deoxyguanosin-N(2)-yl)aristolactam I co-treated with 7-(deoxyadenosin-N(6)--yl)aristolactam II]]; CYP1A2 protein results in increased reduction of and results in increased oxidation of and affects the activity of aristolochic acid I
CTD PMID:21362632, PMID:21932800, PMID:22086975, PMID:26845733 NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
JBrowse link
G Cyp24a1 cytochrome P450, family 24, subfamily a, polypeptide 1 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of CYP24A1 mRNA CTD PMID:23912714 NCBI chr 3:168,097,484...168,111,920
Ensembl chr 3:168,097,485...168,111,920
JBrowse link
G Cyp2c11 cytochrome P450, subfamily 2, polypeptide 11 multiple interactions EXP [aristolochic acid I co-treated with 1-phenylazo-2-naphthol] results in decreased activity of CYP2C11 protein; [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of CYP2C11 mRNA; [CYP2C11 protein co-treated with CYB5A protein] results in increased abundance of aristolochic acid I metabolite; [CYP2C11 protein co-treated with CYB5A protein] results in increased metabolism of aristolochic acid I CTD PMID:21362632, PMID:23912714, PMID:26845733 NCBI chr 1:257,676,172...258,004,428
Ensembl chr 1:257,970,345...258,004,434
JBrowse link
G Cyp2c12 cytochrome P450, family 2, subfamily c, polypeptide 12 multiple interactions EXP [CYP2C12 protein co-treated with CYB5A protein] results in increased abundance of aristolochic acid I metabolite; [CYP2C12 protein co-treated with CYB5A protein] results in increased metabolism of aristolochic acid I CTD PMID:21362632 NCBI chr 1:258,709,726...258,766,873
Ensembl chr 1:258,709,721...258,766,881
JBrowse link
G Cyp2c13 cytochrome P450, family 2, subfamily c, polypeptide 13 multiple interactions EXP [CYP2C13 protein co-treated with CYB5A protein] results in increased abundance of aristolochic acid I metabolite; [CYP2C13 protein co-treated with CYB5A protein] results in increased metabolism of aristolochic acid I CTD PMID:21362632 NCBI chr 1:258,796,624...258,877,023
Ensembl chr 1:258,796,622...258,877,045
JBrowse link
G Cyp2c6v1 cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 multiple interactions EXP [CYP2C6V1 protein co-treated with CYB5A protein] results in increased abundance of aristolochic acid I metabolite; [CYP2C6V1 protein co-treated with CYB5A protein] results in increased metabolism of aristolochic acid I CTD PMID:21362632 NCBI chr 1:147,713,879...147,814,410
Ensembl chr 1:147,713,892...147,888,007
JBrowse link
G Cyp4b1 cytochrome P450, family 4, subfamily b, polypeptide 1 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of CYP4B1 mRNA CTD PMID:23912714 NCBI chr 5:134,508,728...134,526,103
Ensembl chr 5:134,508,730...134,526,089
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 increases expression ISO aristolochic acid I results in increased expression of DDIT3 CTD PMID:22445861 NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
JBrowse link
G Eif2s1 eukaryotic translation initiation factor 2 subunit alpha increases phosphorylation ISO aristolochic acid I results in increased phosphorylation of EIF2S1 protein CTD PMID:22445861 NCBI chr 6:102,048,372...102,073,041
Ensembl chr 6:102,048,372...102,073,041
JBrowse link
G Eloc elongin C multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of ELOC mRNA CTD PMID:23912714 NCBI chr 5:2,042,991...2,059,357
Ensembl chr 5:2,042,991...2,059,351
JBrowse link
G Eno1 enolase 1 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of ENO1 mRNA CTD PMID:23912714 NCBI chr 5:167,288,223...167,299,610
Ensembl chr 5:167,288,223...167,299,609
JBrowse link
G Epas1 endothelial PAS domain protein 1 increases expression ISO aristolochic acid I results in increased expression of EPAS1 protein CTD PMID:21554934 NCBI chr 6:10,306,508...10,385,239
Ensembl chr 6:10,306,405...10,387,265
JBrowse link
G Ephx1 epoxide hydrolase 1 increases expression
multiple interactions
EXP aristolochic acid I results in increased expression of EPHX1 mRNA
[aristolochic acid I co-treated with aristolochic acid II] results in increased expression of EPHX1 mRNA
CTD PMID:17483316, PMID:23912714 NCBI chr13:99,271,390...99,300,580
Ensembl chr13:99,271,366...99,300,579
JBrowse link
G Errfi1 ERBB receptor feedback inhibitor 1 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of ERRFI1 mRNA CTD PMID:23912714 NCBI chr 5:167,951,564...167,966,011
Ensembl chr 5:167,952,728...167,966,009
JBrowse link
G Esm1 endothelial cell-specific molecule 1 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of ESM1 mRNA CTD PMID:23912714 NCBI chr 2:45,104,392...45,113,130
Ensembl chr 2:45,104,305...45,113,131
JBrowse link
G Fbln5 fibulin 5 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of FBLN5 mRNA CTD PMID:23912714 NCBI chr 6:125,644,797...125,723,957
Ensembl chr 6:125,644,804...125,723,944
JBrowse link
G Fcgr3a Fc fragment of IgG receptor IIIa multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of FCGR3A mRNA CTD PMID:23912714 NCBI chr13:89,385,775...89,396,047
Ensembl chr13:89,385,859...89,396,051
JBrowse link
G Fn1 fibronectin 1 multiple interactions ISO [aristolochic acid I co-treated with aristolochic acid II] results in increased secretion of FN1 protein CTD PMID:25663515 NCBI chr 9:78,900,111...78,969,018
Ensembl chr 9:78,900,103...78,969,078
JBrowse link
G G6pc1 glucose-6-phosphatase catalytic subunit 1 decreases expression ISO aristolochic acid I results in decreased expression of G6PC mRNA CTD PMID:31009690 NCBI chr10:89,286,009...89,296,213
Ensembl chr10:89,285,855...89,296,213
JBrowse link
G Gas2 growth arrest-specific 2 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of GAS2 mRNA CTD PMID:23912714 NCBI chr 1:107,234,389...107,363,624
Ensembl chr 1:107,262,659...107,363,788
JBrowse link
G Gata3 GATA binding protein 3 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of GATA3 mRNA CTD PMID:23912714 NCBI chr17:72,419,752...72,452,043
Ensembl chr17:72,429,618...72,450,681
JBrowse link
G Gdf15 growth differentiation factor 15 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of GDF15 mRNA CTD PMID:23912714 NCBI chr16:20,555,395...20,557,978
Ensembl chr16:20,555,395...20,557,978
JBrowse link
G Gnmt glycine N-methyltransferase multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of GNMT mRNA CTD PMID:23912714 NCBI chr 9:16,565,274...16,568,626
Ensembl chr 9:16,565,225...16,568,627
JBrowse link
G Gpm6a glycoprotein m6a multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of GPM6A mRNA CTD PMID:23912714 NCBI chr16:39,367,697...39,719,292
Ensembl chr16:39,367,692...39,719,187
JBrowse link
G Gpt glutamic--pyruvic transaminase multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of GPT mRNA CTD PMID:23912714 NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
JBrowse link
G Gpx2 glutathione peroxidase 2 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of GPX2 mRNA CTD PMID:23912714 NCBI chr 6:99,839,960...99,843,245
Ensembl chr 6:99,839,960...99,843,245
JBrowse link
G Grem1 gremlin 1, DAN family BMP antagonist increases expression
multiple interactions
ISO aristolochic acid I results in increased expression of GREM1 mRNA; aristolochic acid I results in increased expression of GREM1 protein
GREM1 mutant form inhibits the reaction [aristolochic acid I results in decreased activity of BMP7 protein]; GREM1 mutant form inhibits the reaction [aristolochic acid I results in decreased expression of CDH1 protein]; GREM1 mutant form inhibits the reaction [aristolochic acid I results in decreased expression of SMAD1 protein modified form]; GREM1 mutant form inhibits the reaction [aristolochic acid I results in decreased expression of SMAD5 protein modified form]; GREM1 mutant form inhibits the reaction [aristolochic acid I results in decreased expression of SMAD9 protein modified form]; GREM1 mutant form inhibits the reaction [aristolochic acid I results in increased expression of ACTA2 protein]; GREM1 protein inhibits the reaction [BMP7 protein results in decreased susceptibility to aristolochic acid I]
CTD PMID:22525892 NCBI chr 3:105,203,309...105,214,989
Ensembl chr 3:105,203,309...105,214,989
JBrowse link
G Gsta2 glutathione S-transferase alpha 2 increases expression
multiple interactions
EXP aristolochic acid I results in increased expression of GSTA2 mRNA
[aristolochic acid I co-treated with aristolochic acid II] results in increased expression of GSTA3 mRNA
CTD PMID:17483316, PMID:23912714 NCBI chr 8:85,640,081...85,645,621 JBrowse link
G Gstm1 glutathione S-transferase mu 1 increases expression EXP aristolochic acid I results in increased expression of GSTM1 mRNA CTD PMID:17483316 NCBI chr 2:210,803,869...210,809,461
Ensembl chr 2:210,803,869...210,809,306
JBrowse link
G Gstm5 glutathione S-transferase, mu 5 increases expression EXP aristolochic acid I results in increased expression of GSTM3 mRNA CTD PMID:17483316 NCBI chr 2:210,685,338...210,688,133
Ensembl chr 2:210,685,197...210,688,272
JBrowse link
G Gstp1 glutathione S-transferase pi 1 increases expression
multiple interactions
EXP aristolochic acid I results in increased expression of GSTP1 mRNA
[aristolochic acid I co-treated with aristolochic acid II] results in increased expression of GSTP1 mRNA
CTD PMID:17483316, PMID:23912714 NCBI chr 1:219,291,679...219,294,147
Ensembl chr 1:219,291,679...219,294,147
JBrowse link
G Gstt1 glutathione S-transferase theta 1 increases expression EXP aristolochic acid I results in increased expression of GSTT1 mRNA CTD PMID:17483316 NCBI chr20:13,799,102...13,816,527
Ensembl chr20:13,799,102...13,816,526
JBrowse link
G Havcr1 hepatitis A virus cellular receptor 1 increases expression ISO aristolochic acid I results in increased expression of HAVCR1 protein CTD PMID:23019274 NCBI chr10:31,813,819...31,860,934
Ensembl chr10:31,813,814...31,848,379
JBrowse link
G Hcst hematopoietic cell signal transducer multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of HCST mRNA CTD PMID:23912714 NCBI chr 1:88,879,425...88,881,653
Ensembl chr 1:88,879,428...88,881,460
JBrowse link
G Hhip Hedgehog-interacting protein multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of HHIP mRNA CTD PMID:23912714 NCBI chr19:31,525,134...31,614,487
Ensembl chr19:31,524,671...31,614,246
JBrowse link
G Hmmr hyaluronan-mediated motility receptor decreases expression EXP aristolochic acid I results in decreased expression of HMMR mRNA CTD PMID:17483316 NCBI chr10:25,861,490...25,890,639
Ensembl chr10:25,861,490...25,890,639
JBrowse link
G Hmox1 heme oxygenase 1 increases expression
multiple interactions
ISO aristolochic acid I results in increased expression of HMOX1 protein
aristolochic acid I results in increased expression of HMOX1 mRNA; aristolochic acid I results in increased expression of HMOX1 protein
[methyl 2-cyano-3,12-dioxoolean-1,9-dien-28-oate co-treated with aristolochic acid I] results in increased expression of HMOX1 mRNA; methyl 2-cyano-3,12-dioxoolean-1,9-dien-28-oate promotes the reaction [aristolochic acid I results in increased expression of HMOX1 protein]
CTD PMID:24530882, PMID:26260164 NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
JBrowse link
G Hras HRas proto-oncogene, GTPase increases mutagenesis EXP aristolochic acid I results in increased mutagenesis of HRAS gene CTD PMID:21642617 NCBI chr 1:214,178,404...214,181,841
Ensembl chr 1:214,178,407...214,181,686
JBrowse link
G Hsd17b12 hydroxysteroid (17-beta) dehydrogenase 12 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of HSD17B12 mRNA CTD PMID:23912714 NCBI chr 3:82,924,699...83,048,465
Ensembl chr 3:82,924,687...83,048,435
JBrowse link
G Hsp90aa1 heat shock protein 90 alpha family class A member 1 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of HSP90AA1 mRNA CTD PMID:23912714 NCBI chr 6:135,107,262...135,112,793
Ensembl chr 6:135,107,271...135,112,775
JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 increases expression ISO aristolochic acid I results in increased expression of HSPA5 CTD PMID:22445861 NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
JBrowse link
G Hspb2 heat shock protein family B (small) member 2 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of HSPB2 mRNA CTD PMID:23912714 NCBI chr 8:55,176,648...55,178,227
Ensembl chr 8:55,176,847...55,177,818
JBrowse link
G Idh2 isocitrate dehydrogenase (NADP(+)) 2 increases expression ISO aristolochic acid I results in increased expression of IDH2 mRNA CTD PMID:31009690 NCBI chr 1:141,874,354...141,893,674
Ensembl chr 1:141,866,283...141,893,705
JBrowse link
G Idi1 isopentenyl-diphosphate delta isomerase 1 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of IDI1 mRNA CTD PMID:23912714 NCBI chr17:57,976,266...57,984,036
Ensembl chr17:57,976,268...57,984,036
JBrowse link
G Ifng interferon gamma multiple interactions ISO aristolochic acid I inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] affects the localization of NOS2 protein modified form]; aristolochic acid I inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] affects the localization of RELA protein]; aristolochic acid I inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in decreased expression of CCN2 protein]; aristolochic acid I inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; aristolochic acid I inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitrites]; aristolochic acid I inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of IRF1 mRNA]; aristolochic acid I inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of IRF1 protein]; aristolochic acid I inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; aristolochic acid I inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 protein]; aristolochic acid I inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased phosphorylation of NFKBIA protein] CTD PMID:24412304 NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
JBrowse link
G Ik IK cytokine multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of IK mRNA CTD PMID:23912714 NCBI chr18:29,587,901...29,602,705
Ensembl chr18:29,587,901...29,608,338
JBrowse link
G Il6 interleukin 6 multiple interactions
increases secretion
ISO [aristolochic acid I co-treated with aristolochic acid II] results in increased secretion of IL6 protein
aristolochic acid I results in increased secretion of IL6 protein
CTD PMID:25663515, PMID:31048001 NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
JBrowse link
G Irf1 interferon regulatory factor 1 multiple interactions ISO aristolochic acid I inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of IRF1 mRNA]; aristolochic acid I inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of IRF1 protein] CTD PMID:24412304 NCBI chr10:39,109,530...39,116,532
Ensembl chr10:39,109,522...39,116,531
JBrowse link
G Jkamp JNK1/MAPK8-associated membrane protein multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of JKAMP mRNA CTD PMID:23912714 NCBI chr 6:94,835,845...94,849,784
Ensembl chr 6:94,835,845...94,849,784
JBrowse link
G Kcne1 potassium voltage-gated channel subfamily E regulatory subunit 1 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of KCNE1 mRNA CTD PMID:23912714 NCBI chr11:32,498,260...32,511,202
Ensembl chr11:32,498,261...32,508,420
JBrowse link
G Kctd9 potassium channel tetramerization domain containing 9 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of KCTD9 mRNA CTD PMID:23912714 NCBI chr15:44,411,591...44,439,645
Ensembl chr15:44,411,865...44,439,236
JBrowse link
G Keap1 Kelch-like ECH-associated protein 1 increases expression
multiple interactions
ISO aristolochic acid I results in increased expression of KEAP1 protein
methyl 2-cyano-3,12-dioxoolean-1,9-dien-28-oate inhibits the reaction [aristolochic acid I results in increased expression of KEAP1 protein]
CTD PMID:24530882 NCBI chr 8:22,250,518...22,259,868
Ensembl chr 8:22,250,518...22,259,779
JBrowse link
G Klk1c9 kallikrein 1-related peptidase C9 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of KLK1C9 mRNA CTD PMID:23912714 NCBI chr 1:100,086,520...100,090,406
Ensembl chr 1:100,059,967...100,203,329
JBrowse link
G Klk7 kallikrein-related peptidase 7 decreases expression EXP aristolochic acid I results in decreased expression of KLK7 mRNA CTD PMID:17483316 NCBI chr 1:99,749,991...99,754,723
Ensembl chr 1:99,749,936...99,754,435
JBrowse link
G Kras KRAS proto-oncogene, GTPase increases mutagenesis EXP aristolochic acid I results in increased mutagenesis of KRAS gene CTD PMID:21642617 NCBI chr 4:179,482,562...179,515,483
Ensembl chr 4:179,486,105...179,515,558
JBrowse link
G Lcn2 lipocalin 2 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of LCN2 protein CTD PMID:23912714 NCBI chr 3:11,414,189...11,417,534
Ensembl chr 3:11,414,186...11,417,546
JBrowse link
G Ldha lactate dehydrogenase A decreases expression ISO aristolochic acid I results in decreased expression of LDHA mRNA CTD PMID:31009690 NCBI chr 1:102,900,288...102,909,713
Ensembl chr 1:102,900,286...102,909,707
JBrowse link
G Lhx1 LIM homeobox 1 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of LHX1 mRNA CTD PMID:23912714 NCBI chr10:71,843,991...71,849,293
Ensembl chr10:71,843,991...71,849,293
JBrowse link
G Ly6al lymphocyte antigen 6 complex, locus A-like multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of LY6AL mRNA CTD PMID:23912714 NCBI chr 7:116,557,519...116,561,058
Ensembl chr 7:116,557,519...116,561,208
JBrowse link
G Maf MAF bZIP transcription factor multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of MAF mRNA CTD PMID:23912714 NCBI chr19:48,179,826...48,200,995
Ensembl chr19:48,194,804...48,196,748
JBrowse link
G Mapk1 mitogen activated protein kinase 1 increases phosphorylation
decreases phosphorylation
ISO aristolochic acid I results in increased phosphorylation of MAPK1 protein
aristolochic acid I results in decreased phosphorylation of MAPK1 protein
CTD PMID:21300145, PMID:26656393 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 increases phosphorylation
decreases phosphorylation
ISO aristolochic acid I results in increased phosphorylation of MAPK3 protein
aristolochic acid I results in decreased phosphorylation of MAPK3 protein
CTD PMID:21300145, PMID:26656393 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Mettl7b methyltransferase like 7B multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of METTL7B mRNA CTD PMID:23912714 NCBI chr 7:3,383,876...3,386,522
Ensembl chr 7:3,383,879...3,386,522
JBrowse link
G Mgmt O-6-methylguanine-DNA methyltransferase multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of MGMT mRNA CTD PMID:23912714 NCBI chr 1:209,237,255...209,464,189
Ensembl chr 1:209,237,233...209,464,190
JBrowse link
G Mid1ip1 MID1 interacting protein 1 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of MID1IP1 mRNA CTD PMID:23912714 NCBI chr  X:13,114,557...13,119,274
Ensembl chr  X:13,114,569...13,116,743
JBrowse link
G Mir10b microRNA 10b decreases expression EXP aristolochic acid I results in decreased expression of MIR10B mRNA CTD PMID:27422293 NCBI chr 3:61,647,978...61,648,086
Ensembl chr 3:61,647,978...61,648,086
JBrowse link
G Mir192 microRNA 192 decreases expression EXP aristolochic acid I results in decreased expression of MIR192 mRNA CTD PMID:27422293 NCBI chr 1:221,634,971...221,635,080
Ensembl chr 1:221,634,971...221,635,080
JBrowse link
G Mir21 microRNA 21 increases expression EXP aristolochic acid I results in increased expression of MIR21 mRNA CTD PMID:27422293 NCBI chr10:73,902,210...73,902,301
Ensembl chr10:73,902,210...73,902,301
JBrowse link
G Mir23a microRNA 23a increases expression EXP aristolochic acid I results in increased expression of MIR23A mRNA CTD PMID:27422293 NCBI chr19:25,318,582...25,318,656
Ensembl chr19:25,318,582...25,318,656
JBrowse link
G Mir33 microRNA 33 decreases expression EXP aristolochic acid I results in decreased expression of MIR33 mRNA CTD PMID:27422293 NCBI chr 7:123,431,612...123,431,680
Ensembl chr 7:123,431,612...123,431,680
JBrowse link
G Mir331 microRNA 331 decreases expression EXP aristolochic acid I results in decreased expression of MIR331 mRNA CTD PMID:27422293 NCBI chr 7:34,881,095...34,881,190
Ensembl chr 7:34,881,095...34,881,190
JBrowse link
G Mir3473 microRNA 3473 increases expression EXP aristolochic acid I results in increased expression of MIR3473 mRNA CTD PMID:27422293 NCBI chr13:44,719,335...44,719,401
Ensembl chr13:44,719,335...44,719,401
JBrowse link
G Mir34a microRNA 34a increases expression EXP aristolochic acid I results in increased expression of MIR34A mRNA CTD PMID:27422293 NCBI chr 5:167,092,491...167,092,592
Ensembl chr 5:167,092,491...167,092,592
JBrowse link
G Mir3580 microRNA 3580 decreases expression EXP aristolochic acid I results in decreased expression of MIR3580 mRNA CTD PMID:27422293 NCBI chr  X:151,295,615...151,295,695
Ensembl chr  X:151,295,615...151,295,695
JBrowse link
G Mir3593 microRNA 3593 decreases expression EXP aristolochic acid I results in decreased expression of MIR3593 mRNA CTD PMID:27422293 NCBI chr 6:76,661,799...76,661,889
Ensembl chr 6:76,661,799...76,661,889
JBrowse link
G Mir451a microRNA 451a decreases expression EXP aristolochic acid I results in decreased expression of MIR451A mRNA CTD PMID:27422293 NCBI chr10:65,291,204...65,291,275
Ensembl chr10:65,291,204...65,291,275
JBrowse link
G Mir489 microRNA 489 decreases expression EXP aristolochic acid I results in decreased expression of MIR489 mRNA CTD PMID:27422293 NCBI chr 4:28,659,523...28,659,628
Ensembl chr 4:28,659,523...28,659,628
JBrowse link
G Mir551b microRNA 551b increases expression EXP aristolochic acid I results in increased expression of MIR551B mRNA CTD PMID:27422293 NCBI chr 2:116,867,647...116,867,744
Ensembl chr 2:116,867,647...116,867,744
JBrowse link
G Mir6216 microRNA 6216 increases expression EXP aristolochic acid I results in increased expression of MIR6216 mRNA CTD PMID:27422293 NCBI chr 3:46,361,908...46,361,985
Ensembl chr 3:46,361,908...46,361,985
JBrowse link
G Mir6324 microRNA 6324 increases expression EXP aristolochic acid I results in increased expression of MIR6324 mRNA CTD PMID:27422293 NCBI chr11:36,383,529...36,383,649
Ensembl chr11:36,383,529...36,383,649
JBrowse link
G Mir99a microRNA 99a decreases expression EXP aristolochic acid I results in decreased expression of MIR99A mRNA CTD PMID:27422293 NCBI chr11:16,052,153...16,052,233
Ensembl chr11:16,052,153...16,052,233
JBrowse link
G Mybl1 MYB proto-oncogene like 1 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of MYBL1 mRNA CTD PMID:23912714 NCBI chr 5:9,279,756...9,315,112
Ensembl chr 5:9,279,970...9,315,114
JBrowse link
G Nadsyn1 NAD synthetase 1 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of NADSYN1 mRNA CTD PMID:23912714 NCBI chr 1:216,985,710...217,013,743
Ensembl chr 1:216,985,714...217,013,702
JBrowse link
G Nat8f3 N-acetyltransferase 8 (GCN5-related) family member 3 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of NAT8F3 mRNA CTD PMID:23912714 NCBI chr 4:117,488,089...117,492,315
Ensembl chr 4:117,490,035...117,490,721
JBrowse link
G Nbn nibrin multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of NBN mRNA CTD PMID:23912714 NCBI chr 5:29,622,347...29,656,877
Ensembl chr 5:29,622,281...29,656,864
JBrowse link
G Nck1 NCK adaptor protein 1 multiple interactions ISO aristolochic acid I inhibits the reaction [SLIT2 protein results in increased expression of NCK1 mRNA]; aristolochic acid I inhibits the reaction [SLIT2 protein results in increased expression of NCK1 protein]; NCK1 protein inhibits the reaction [aristolochic acid I inhibits the reaction [SLIT2 protein results in increased activity of RAC1 protein]]; NCK1 protein inhibits the reaction [aristolochic acid I inhibits the reaction [SLIT2 protein results in increased expression of NCK2 mRNA]]; NCK1 protein inhibits the reaction [aristolochic acid I inhibits the reaction [SLIT2 protein results in increased expression of NCK2 protein]] CTD PMID:30381256 NCBI chr 8:108,787,797...108,847,779
Ensembl chr 8:108,787,798...108,847,779
JBrowse link
G Nck2 NCK adaptor protein 2 multiple interactions ISO aristolochic acid I inhibits the reaction [SLIT2 protein results in increased expression of NCK2 mRNA]; aristolochic acid I inhibits the reaction [SLIT2 protein results in increased expression of NCK2 protein]; NCK1 protein inhibits the reaction [aristolochic acid I inhibits the reaction [SLIT2 protein results in increased expression of NCK2 mRNA]]; NCK1 protein inhibits the reaction [aristolochic acid I inhibits the reaction [SLIT2 protein results in increased expression of NCK2 protein]] CTD PMID:30381256 NCBI chr 9:50,246,767...50,373,307
Ensembl chr 9:50,247,692...50,373,284
JBrowse link
G Nfe2l2 nuclear factor, erythroid 2-like 2 multiple interactions
decreases expression
ISO aristolochic acid I results in decreased expression of and affects the localization of NFE2L2 protein; methyl 2-cyano-3,12-dioxoolean-1,9-dien-28-oate inhibits the reaction [aristolochic acid I results in decreased expression of and affects the localization of NFE2L2 protein]; methyl 2-cyano-3,12-dioxoolean-1,9-dien-28-oate inhibits the reaction [aristolochic acid I results in decreased expression of NFE2L2 mRNA] CTD PMID:24530882 NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions ISO aristolochic acid I inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased phosphorylation of NFKBIA protein]; aristolochic acid I inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein] CTD PMID:21291967, PMID:24412304 NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
JBrowse link
G Nme7 NME/NM23 family member 7 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of NME7 mRNA CTD PMID:23912714 NCBI chr13:82,607,844...82,737,383
Ensembl chr13:82,626,685...82,737,343
JBrowse link
G Nop53 NOP53 ribosome biogenesis factor multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of NOP53 mRNA CTD PMID:23912714 NCBI chr 1:77,836,522...77,843,991
Ensembl chr 1:77,836,196...77,844,189
JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions ISO aristolochic acid I inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] affects the localization of NOS2 protein modified form]; aristolochic acid I inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; aristolochic acid I inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 protein]; aristolochic acid I inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; aristolochic acid I inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] CTD PMID:21291967, PMID:24412304 NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
JBrowse link
G Nphs2 NPHS2 stomatin family member, podocin multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of NPHS2 mRNA CTD PMID:23912714 NCBI chr13:73,929,136...73,941,522
Ensembl chr13:73,929,136...73,941,522
JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 multiple interactions
increases activity
increases expression
ISO
EXP
[Dicumarol results in decreased activity of NQO1 protein] which results in increased abundance of aristolochic acid I; [Dicumarol results in decreased activity of NQO1 protein] which results in increased abundance of aristolochic acid I metabolite; [methyl 2-cyano-3,12-dioxoolean-1,9-dien-28-oate co-treated with aristolochic acid I] results in increased expression of NQO1 mRNA; [methyl 2-cyano-3,12-dioxoolean-1,9-dien-28-oate co-treated with aristolochic acid I] results in increased expression of NQO1 protein; [Phenindione results in decreased activity of NQO1 protein] which results in increased abundance of aristolochic acid I; [Phenindione results in decreased activity of NQO1 protein] which results in increased abundance of aristolochic acid I metabolite; TRP53 protein affects the reaction [aristolochic acid I results in increased expression of NQO1 protein]
[1-phenylazo-2-naphthol co-treated with aristolochic acid I] results in increased expression of NQO1 mRNA; [aristolochic acid I co-treated with 1-phenylazo-2-naphthol] results in increased expression of and results in increased activity of NQO1 protein; [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of NQO1 mRNA
aristolochic acid I results in increased activity of NQO1 protein
aristolochic acid I results in increased expression of NQO1 mRNA; aristolochic acid I results in increased expression of NQO1 protein
CTD PMID:17483316, PMID:21613233, PMID:23912714, PMID:24530882, PMID:25209566, PMID:25230394, PMID:26845733, PMID:27557898, PMID:31602497 NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
JBrowse link
G Nr1d1 nuclear receptor subfamily 1, group D, member 1 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of NR1D1 mRNA CTD PMID:23912714 NCBI chr10:86,683,875...86,690,815
Ensembl chr10:86,683,875...86,690,815
JBrowse link
G Oxnad1 oxidoreductase NAD-binding domain containing 1 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of OXNAD1 mRNA CTD PMID:23912714 NCBI chr16:8,207,223...8,236,292
Ensembl chr16:8,207,223...8,236,292
JBrowse link
G Oxr1 oxidation resistance 1 increases expression EXP aristolochic acid I results in increased expression of OXR1 mRNA CTD PMID:17483316 NCBI chr 7:80,351,774...80,788,094
Ensembl chr 7:80,351,774...80,788,094
JBrowse link
G Pabpc1 poly(A) binding protein, cytoplasmic 1 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of PABPC1 mRNA CTD PMID:23912714 NCBI chr 7:75,409,581...75,421,874
Ensembl chr 7:75,409,581...75,422,268
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases expression
increases cleavage
EXP
ISO
3-methyladenine inhibits the reaction [aristolochic acid I results in increased cleavage of PARP1 protein]; ATG5 affects the reaction [aristolochic acid I results in increased cleavage of PARP1 protein]
aristolochic acid I results in increased expression of PARP1 protein modified form
CTD PMID:23939141, PMID:26656393 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link
G Pck1 phosphoenolpyruvate carboxykinase 1 decreases expression ISO aristolochic acid I results in decreased expression of PCK1 mRNA CTD PMID:31009690 NCBI chr 3:171,213,936...171,219,885
Ensembl chr 3:171,213,936...171,219,871
JBrowse link
G Pfkl phosphofructokinase, liver type decreases expression ISO aristolochic acid I results in decreased expression of PFKL mRNA CTD PMID:31009690 NCBI chr20:11,393,860...11,415,889
Ensembl chr20:11,393,877...11,415,882
JBrowse link
G Pklr pyruvate kinase L/R multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of PKLR mRNA CTD PMID:23912714 NCBI chr 2:188,449,158...188,458,034
Ensembl chr 2:188,449,210...188,459,592
JBrowse link
G Pmaip1 phorbol-12-myristate-13-acetate-induced protein 1 increases expression ISO aristolochic acid I results in increased expression of PMAIP1 mRNA CTD PMID:26260164 NCBI chr18:62,159,128...62,179,635
Ensembl chr18:62,174,670...62,181,102
JBrowse link
G Por cytochrome p450 oxidoreductase multiple interactions
increases metabolic processing
affects abundance
ISO
EXP
[CYP1A1 protein co-treated with CYP1A2 protein] affects the reaction [[Thioctic Acid results in decreased activity of POR protein] inhibits the reaction [aristolochic acid I results in increased abundance of [7-(deoxyadenosin-N(6)-yl)aristolactam I co-treated with 7-(deoxyguanosin-N(2)-yl)aristolactam I co-treated with 7-(deoxyadenosin-N(6)--yl)aristolactam II]]]; [Thioctic Acid results in decreased activity of POR protein] inhibits the reaction [aristolochic acid I results in increased abundance of [7-(deoxyadenosin-N(6)-yl)aristolactam I co-treated with 7-(deoxyguanosin-N(2)-yl)aristolactam I co-treated with 7-(deoxyadenosin-N(6)--yl)aristolactam II]]; CYP1A1 protein affects the reaction [[Thioctic Acid results in decreased activity of POR protein] inhibits the reaction [aristolochic acid I results in increased abundance of [7-(deoxyadenosin-N(6)-yl)aristolactam I co-treated with 7-(deoxyguanosin-N(2)-yl)aristolactam I co-treated with 7-(deoxyadenosin-N(6)--yl)aristolactam II]]]; POR protein affects the abundance of and affects the metabolism of aristolochic acid I
POR protein results in increased metabolism of aristolochic acid I
POR protein affects the abundance of aristolochic acid I metabolite
CTD PMID:21362632, PMID:21932800, PMID:26845733 NCBI chr12:23,998,411...24,017,063
Ensembl chr12:23,998,411...24,046,814
JBrowse link
G Prss35 serine protease 35 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of PRSS35 mRNA CTD PMID:23912714 NCBI chr 8:94,423,629...94,440,509
Ensembl chr 8:94,423,808...94,440,503
JBrowse link
G Psma1 proteasome 20S subunit alpha 1 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of PSMA1 mRNA CTD PMID:23912714 NCBI chr 1:183,733,567...183,744,586
Ensembl chr 1:183,733,567...183,744,586
JBrowse link
G Ptprcap protein tyrosine phosphatase, receptor type, C-associated protein multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of PTPRCAP mRNA CTD PMID:23912714 NCBI chr 1:219,403,970...219,406,129
Ensembl chr 1:219,403,970...219,406,128
JBrowse link
G Rac1 Rac family small GTPase 1 multiple interactions ISO aristolochic acid I inhibits the reaction [SLIT2 protein results in increased activity of RAC1 protein]; NCK1 protein inhibits the reaction [aristolochic acid I inhibits the reaction [SLIT2 protein results in increased activity of RAC1 protein]] CTD PMID:30381256 NCBI chr12:13,090,316...13,111,841
Ensembl chr12:13,090,172...13,111,873
JBrowse link
G Rbm25 RNA binding motif protein 25 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of RBM25 mRNA CTD PMID:23912714 NCBI chr 6:107,117,888...107,165,538 JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO aristolochic acid I inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] affects the localization of RELA protein]
aristolochic acid I inhibits the reaction [4-phenylenediamine results in increased phosphorylation of RELA protein]; aristolochic acid I inhibits the reaction [Dinitrochlorobenzene results in increased phosphorylation of RELA protein]
CTD PMID:24412304, PMID:31226360 NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
JBrowse link
G Rgn regucalcin multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of RGN mRNA CTD PMID:23912714 NCBI chr  X:1,833,484...1,848,904
Ensembl chr  X:1,833,492...1,848,904
JBrowse link
G Robo1 roundabout guidance receptor 1 decreases expression ISO aristolochic acid I results in decreased expression of ROBO1 mRNA; aristolochic acid I results in decreased expression of ROBO1 protein CTD PMID:30381256 NCBI chr11:9,079,291...10,146,302
Ensembl chr11:9,642,365...10,143,317
JBrowse link
G Robo2 roundabout guidance receptor 2 decreases expression ISO aristolochic acid I results in decreased expression of ROBO2 mRNA; aristolochic acid I results in decreased expression of ROBO2 protein CTD PMID:30381256 NCBI chr11:11,062,866...12,618,793
Ensembl chr11:11,062,790...11,585,765
JBrowse link
G Rps9 ribosomal protein S9 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of RPS9 mRNA CTD PMID:23912714 NCBI chr 1:64,086,625...64,090,023
Ensembl chr 1:64,018,125...64,090,021
JBrowse link
G Scin scinderin multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of SCIN mRNA CTD PMID:23912714 NCBI chr 6:59,975,375...60,055,075
Ensembl chr 6:59,976,003...60,054,279
JBrowse link
G Serpina10 serpin family A member 10 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of SERPINA10 mRNA CTD PMID:23912714 NCBI chr 6:127,500,014...127,508,470
Ensembl chr 6:127,500,016...127,508,452
JBrowse link
G Sfrp2 secreted frizzled-related protein 2 decreases expression EXP aristolochic acid I results in decreased expression of SFRP2 mRNA CTD PMID:17483316 NCBI chr 2:182,723,732...182,731,277
Ensembl chr 2:182,723,854...182,731,764
JBrowse link
G Sgk1 serum/glucocorticoid regulated kinase 1 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of SGK1 mRNA CTD PMID:23912714 NCBI chr 1:24,185,451...24,302,309
Ensembl chr 1:24,185,435...24,302,298
JBrowse link
G Slc16a4 solute carrier family 16, member 4 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of SLC16A4 mRNA CTD PMID:23912714 NCBI chr 2:210,045,122...210,161,017
Ensembl chr 2:210,045,161...210,068,502
JBrowse link
G Slc22a6 solute carrier family 22 member 6 multiple interactions ISO [wedelolactone results in decreased activity of SLC22A6 protein] which results in increased susceptibility to and results in increased activity of aristolochic acid I; [wogonin results in decreased activity of SLC22A6 protein] which results in increased susceptibility to and results in increased activity of aristolochic acid I; aristolochic acid I inhibits the reaction [SLC22A6 results in increased uptake of p-Aminohippuric Acid]; aristolochic acid I promotes the reaction [SLC22A6 results in increased export of p-Aminohippuric Acid] CTD PMID:19643159, PMID:32159797 NCBI chr 1:224,824,809...224,833,284
Ensembl chr 1:224,824,799...224,833,259
JBrowse link
G Slc22a8 solute carrier family 22 member 8 multiple interactions ISO [wedelolactone results in decreased activity of SLC22A8 protein] which results in increased susceptibility to and results in increased activity of aristolochic acid I; [wogonin results in decreased activity of SLC22A8 protein] which results in increased susceptibility to and results in increased activity of aristolochic acid I; aristolochic acid I inhibits the reaction [SLC22A8 results in increased uptake of estrone sulfate]; aristolochic acid I promotes the reaction [SLC22A8 results in increased export of p-Aminohippuric Acid] CTD PMID:19643159, PMID:32159797 NCBI chr 1:224,799,444...224,818,482
Ensembl chr 1:224,800,252...224,818,482
JBrowse link
G Slc26a1 solute carrier family 26 member 1 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of SLC26A1 mRNA CTD PMID:23912714 NCBI chr14:2,050,805...2,056,091
Ensembl chr14:2,050,483...2,056,089
JBrowse link
G Slc2a8 solute carrier family 2 member 8 decreases expression ISO aristolochic acid I results in decreased expression of SLC2A8 mRNA CTD PMID:31009690 NCBI chr 3:12,020,227...12,029,920
Ensembl chr 3:12,020,229...12,029,877
JBrowse link
G Slc35a3 solute carrier family 35 member A3 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of SLC35A3 mRNA CTD PMID:23912714 NCBI chr 2:219,705,618...219,741,886
Ensembl chr 2:219,705,620...219,741,886
JBrowse link
G Slc51b solute carrier family 51 subunit beta multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of SLC51B mRNA CTD PMID:23912714 NCBI chr 8:70,930,196...70,938,559
Ensembl chr 8:70,930,347...70,932,986
JBrowse link
G Slfn4 schlafen family member 4 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of SLFN4 mRNA CTD PMID:23912714 NCBI chr10:70,411,686...70,435,162
Ensembl chr10:70,411,738...70,435,156
JBrowse link
G Slit2 slit guidance ligand 2 decreases expression
multiple interactions
ISO aristolochic acid I results in decreased expression of SLIT2 mRNA; aristolochic acid I results in decreased expression of SLIT2 protein
aristolochic acid I inhibits the reaction [SLIT2 protein results in increased activity of RAC1 protein]; aristolochic acid I inhibits the reaction [SLIT2 protein results in increased expression of NCK1 mRNA]; aristolochic acid I inhibits the reaction [SLIT2 protein results in increased expression of NCK1 protein]; aristolochic acid I inhibits the reaction [SLIT2 protein results in increased expression of NCK2 mRNA]; aristolochic acid I inhibits the reaction [SLIT2 protein results in increased expression of NCK2 protein]; NCK1 protein inhibits the reaction [aristolochic acid I inhibits the reaction [SLIT2 protein results in increased activity of RAC1 protein]]; NCK1 protein inhibits the reaction [aristolochic acid I inhibits the reaction [SLIT2 protein results in increased expression of NCK2 mRNA]]; NCK1 protein inhibits the reaction [aristolochic acid I inhibits the reaction [SLIT2 protein results in increased expression of NCK2 protein]]
CTD PMID:30381256 NCBI chr14:66,831,848...67,171,491
Ensembl chr14:66,831,848...67,170,361
JBrowse link
G Smad1 SMAD family member 1 decreases expression
multiple interactions
ISO aristolochic acid I results in decreased expression of SMAD1 protein modified form
GREM1 mutant form inhibits the reaction [aristolochic acid I results in decreased expression of SMAD1 protein modified form]
CTD PMID:22525892 NCBI chr19:32,182,942...32,248,694
Ensembl chr19:32,188,267...32,248,684
JBrowse link
G Smad5 SMAD family member 5 decreases expression
multiple interactions
ISO aristolochic acid I results in decreased expression of SMAD5 protein modified form
GREM1 mutant form inhibits the reaction [aristolochic acid I results in decreased expression of SMAD5 protein modified form]
CTD PMID:22525892 NCBI chr17:8,307,448...8,336,996
Ensembl chr17:8,311,796...8,331,032
JBrowse link
G Smad9 SMAD family member 9 decreases expression
multiple interactions
ISO aristolochic acid I results in decreased expression of SMAD9 protein modified form
GREM1 mutant form inhibits the reaction [aristolochic acid I results in decreased expression of SMAD9 protein modified form]
CTD PMID:22525892 NCBI chr 2:143,951,725...144,002,025
Ensembl chr 2:144,191,846...144,212,138
Ensembl chr 2:144,191,846...144,212,138
JBrowse link
G Snca synuclein alpha multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of SNCA mRNA CTD PMID:23912714 NCBI chr 4:90,782,412...90,883,236
Ensembl chr 4:90,782,374...90,882,285
JBrowse link
G Spata22 spermatogenesis associated 22 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of SPATA22 mRNA CTD PMID:23912714 NCBI chr10:59,893,064...59,910,769
Ensembl chr10:59,879,850...59,911,051
JBrowse link
G Spp1 secreted phosphoprotein 1 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of SPP1 protein CTD PMID:23912714 NCBI chr14:6,673,686...6,679,965
Ensembl chr14:6,673,686...6,679,901
JBrowse link
G Ssb small RNA binding exonuclease protection factor La multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of SSB mRNA CTD PMID:23912714 NCBI chr 3:56,092,425...56,102,008
Ensembl chr 3:56,092,501...56,102,001
JBrowse link
G Ssr3 signal sequence receptor subunit 3 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of SSR3 mRNA CTD PMID:23912714 NCBI chr 2:156,010,997...156,023,853
Ensembl chr 2:156,011,002...156,014,527
JBrowse link
G St6galnac2 ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 2 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of ST6GALNAC2 mRNA CTD PMID:23912714 NCBI chr10:105,650,866...105,668,579
Ensembl chr10:105,650,862...105,668,593
JBrowse link
G Strn3 striatin 3 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of STRN3 mRNA CTD PMID:23912714 NCBI chr 6:72,376,360...72,462,676
Ensembl chr 6:72,376,330...72,462,658
JBrowse link
G Sult1a1 sulfotransferase family 1A member 1 multiple interactions ISO SULT1A1 protein results in increased metabolism of and results in increased susceptibility to aristolochic acid I; SULT1A1 protein results in increased metabolism of and results in increased susceptibility to aristolochic acid I metabolite CTD PMID:27207664 NCBI chr 1:198,100,586...198,104,106
Ensembl chr 1:198,100,586...198,104,109
JBrowse link
G Sult1b1 sulfotransferase family 1B member 1 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of SULT1B1 mRNA CTD PMID:23912714 NCBI chr14:22,142,412...22,155,246
Ensembl chr14:22,142,364...22,155,231
JBrowse link
G Sv2b synaptic vesicle glycoprotein 2b multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of SV2B mRNA CTD PMID:23912714 NCBI chr 1:136,664,199...136,842,247
Ensembl chr 1:136,664,204...136,842,247
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions
increases expression
EXP
ISO
[aristolochic acid I co-treated with aristolochic acid II] results in increased secretion of TGFB1 protein
aristolochic acid I results in increased expression of TGFB1 mRNA; aristolochic acid I results in increased expression of TGFB1 protein
CTD PMID:25663515, PMID:31048001 NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
JBrowse link
G Tnf tumor necrosis factor multiple interactions
increases expression
increases secretion
ISO aristolochic acid I inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]
aristolochic acid I results in increased expression of TNF protein
aristolochic acid I results in increased secretion of TNF protein
CTD PMID:21291967, PMID:31009690, PMID:31048001 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Tp53 tumor protein p53 increases expression
affects response to substance
multiple interactions
ISO aristolochic acid I results in increased expression of TRP53 protein
TRP53 protein affects the susceptibility to aristolochic acid I
TRP53 protein affects the reaction [aristolochic acid I results in increased expression of H2AFX protein]; TRP53 protein affects the reaction [aristolochic acid I results in increased expression of NQO1 protein]
CTD PMID:31602497 NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
JBrowse link
G Ucp3 uncoupling protein 3 decreases expression ISO aristolochic acid I results in decreased expression of UCP3 mRNA CTD PMID:31009690 NCBI chr 1:165,482,912...165,495,895
Ensembl chr 1:165,482,155...165,496,206
JBrowse link
G Ugt1a1 UDP glucuronosyltransferase family 1 member A1 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of UGT1A1 mRNA CTD PMID:23912714 NCBI chr 9:95,295,701...95,302,822
Ensembl chr 9:95,161,157...95,302,822
JBrowse link
G Ugt1a6 UDP glucuronosyltransferase family 1 member A6 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of UGT1A6 mRNA CTD PMID:23912714 NCBI chr 9:95,241,609...95,302,822
Ensembl chr 9:95,161,157...95,302,822
JBrowse link
G Ugt2b17 UDP glucuronosyltransferase family 2 member B17 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of UGT2B17 mRNA CTD PMID:23912714 NCBI chr14:22,724,399...22,736,148
Ensembl chr14:22,724,070...22,825,444
JBrowse link
G Ugt2b35 UDP glucuronosyltransferase 2 family, polypeptide B35 increases expression EXP aristolochic acid I results in increased expression of UGT2B15 mRNA CTD PMID:17483316 NCBI chr14:22,553,633...22,591,461
Ensembl chr14:22,553,650...22,591,461
JBrowse link
G Ugt2b7 UDP glucuronosyltransferase family 2 member B7 increases expression
multiple interactions
EXP aristolochic acid I results in increased expression of UGT2B7 mRNA
[aristolochic acid I co-treated with aristolochic acid II] results in increased expression of UGT2B7 mRNA
CTD PMID:17483316, PMID:23912714 NCBI chr14:22,597,103...22,619,968 JBrowse link
G Vegfa vascular endothelial growth factor A increases expression
multiple interactions
ISO aristolochic acid I results in increased expression of VEGFA mRNA; aristolochic acid I results in increased expression of VEGFA protein
chetomin inhibits the reaction [aristolochic acid I results in increased expression of VEGFA protein]; mithramycin A inhibits the reaction [aristolochic acid I results in increased expression of VEGFA mRNA]; mithramycin A inhibits the reaction [aristolochic acid I results in increased expression of VEGFA protein]
CTD PMID:21554934 NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
JBrowse link
G Vim vimentin multiple interactions EXP
ISO
[aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of VIM mRNA; [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of VIM protein
[aristolochic acid I co-treated with aristolochic acid II] results in increased expression of VIM protein; BMP7 protein inhibits the reaction [[aristolochic acid I co-treated with aristolochic acid II] results in increased expression of VIM protein]; BMP7 protein promotes the reaction [[aristolochic acid I co-treated with aristolochic acid II] results in increased expression of VIM protein]
CTD PMID:23912714, PMID:25663515 NCBI chr17:80,882,715...80,891,200
Ensembl chr17:80,882,666...80,891,212
JBrowse link
G Xbp1 X-box binding protein 1 increases splicing ISO aristolochic acid I results in increased splicing of XBP1 mRNA CTD PMID:22445861 NCBI chr14:85,753,736...85,758,820
Ensembl chr14:85,753,760...85,758,145
JBrowse link
G Zfp36l1 zinc finger protein 36, C3H type-like 1 multiple interactions EXP [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of ZFP36L1 mRNA CTD PMID:23912714 NCBI chr 6:103,308,032...103,313,074
Ensembl chr 6:103,308,045...103,313,074
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19816
    role 19764
      biological role 19764
        biochemical role 19313
          metabolite 19294
            aristolochic acid 212
              aristoloterpenate-I 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 19816
    subatomic particle 19814
      composite particle 19814
        hadron 19814
          baryon 19814
            nucleon 19814
              atomic nucleus 19814
                atom 19814
                  main group element atom 19702
                    p-block element atom 19702
                      carbon group element atom 19608
                        carbon atom 19597
                          organic molecular entity 19597
                            organic group 18537
                              organic divalent group 18530
                                organodiyl group 18530
                                  carbonyl group 18436
                                    carbonyl compound 18436
                                      carboxylic acid 18114
                                        monocarboxylic acid 17476
                                          aristolochic acid 212
                                            aristoloterpenate-I 0
paths to the root

NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.